DOVER, DE, Lomond Therapeutics Holdings, a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, announced $20 million private placement financing.
Lomond Therapeutics Holdings, a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, announced the addition of two new investors, Yosemite Capital and QIA Investments, coincident with a second and third closing, respectively, and the raising of an additional $20 million private placement financing.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
